The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 25, 2022
Filed:
Nov. 01, 2019
Applicant:
Imago Biosciences, Inc., San Carlos, CA (US);
Inventors:
Hugh Y. Rienhoff, Jr., San Carlos, CA (US);
John M. McCall, Boca Grande, FL (US);
Michael Clare, Skokie, IL (US);
Cassandra Celatka, Hull, MD (US);
Amy E. Tapper, Boston, MA (US);
Assignee:
Imago Biosciences, Inc., San Carlos, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/397 (2006.01); C07D 249/06 (2006.01); C07C 309/30 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01); C07D 239/26 (2006.01); A61K 31/506 (2006.01); C07D 295/192 (2006.01); A61K 31/495 (2006.01); C07D 279/12 (2006.01); A61K 31/54 (2006.01); C07D 205/04 (2006.01); C07D 295/26 (2006.01); C07D 215/54 (2006.01); C07C 53/18 (2006.01); C07D 231/12 (2006.01); C07D 263/32 (2006.01); A61K 31/541 (2006.01); C07B 59/00 (2006.01); C07D 403/12 (2006.01); A61K 31/4192 (2006.01); C07D 401/12 (2006.01); A61K 31/454 (2006.01); C07D 249/08 (2006.01); A61K 31/4196 (2006.01); C07D 211/66 (2006.01); A61K 31/445 (2006.01); C07D 239/42 (2006.01); C07D 491/107 (2006.01); C07D 413/12 (2006.01); A61K 31/5377 (2006.01); C07D 498/08 (2006.01); A61K 31/5383 (2006.01); C07D 471/10 (2006.01); A61K 31/435 (2006.01); C07D 401/04 (2006.01); A61K 31/41 (2006.01); C07D 487/04 (2006.01); A61K 31/4162 (2006.01); C07D 487/08 (2006.01); A61K 31/4995 (2006.01); A61K 31/551 (2006.01); C07D 237/08 (2006.01); A61K 31/501 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 43/00 (2006.01);
U.S. Cl.
CPC ...
C07D 249/06 (2013.01); A61K 9/0053 (2013.01); A61K 9/1623 (2013.01); A61K 9/4858 (2013.01); A61K 31/397 (2013.01); A61K 31/41 (2013.01); A61K 31/4162 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/435 (2013.01); A61K 31/445 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/4995 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/54 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 43/00 (2018.01); C07B 59/002 (2013.01); C07C 53/18 (2013.01); C07C 309/30 (2013.01); C07D 205/04 (2013.01); C07D 211/66 (2013.01); C07D 215/54 (2013.01); C07D 231/12 (2013.01); C07D 237/08 (2013.01); C07D 239/26 (2013.01); C07D 239/42 (2013.01); C07D 249/08 (2013.01); C07D 263/32 (2013.01); C07D 279/12 (2013.01); C07D 295/192 (2013.01); C07D 295/26 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01); C07B 2200/05 (2013.01); C07B 2200/07 (2013.01); C07B 2200/13 (2013.01);
Abstract
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.